Screening procedure to identify triazole-resistant *Aspergillus fumigatus* using agar plates

1.0 Purpose/Principle

The environmental mold *Aspergillus fumigatus* is the primary cause of invasive aspergillosis. In patients with high-risk conditions, mortality exceeds 50%. Triazole antifungals have greatly improved survival; however, triazole-resistant *A. fumigatus* infections are increasingly reported worldwide and are associated with increased treatment failure and mortality. This procedure will be used for screening *Aspergillus fumigatus* isolates for azole antifungal resistance using a 4-quadrant agar plate with antifungals. Understanding the prevalence of such isolates in patients is important to guide clinical and public health decision making. Triazole-resistance must be confirmed through testing using broth microdilution.

2.0 Scope

Although this media can be used for the screening of any *Aspergillus* species for resistance to azoles, this procedure is written primarily for use with *A. fumigatus*. This procedure outlines how to: 1) create 4-well screening plates, 2) process isolates, 3) inoculate *Aspergillus* screening plates and record the results, and 4) Store the isolates.

3.0 Definitions

<table>
<thead>
<tr>
<th>AFIS</th>
<th><em>Aspergillus fumigatus</em> itraconazole susceptibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSC</td>
<td>Biological safety cabinet</td>
</tr>
</tbody>
</table>

4.0 Equipment: Properly maintained and calibrated per institutions protocols

- Stir plate /Sterile stir bars
- Water bath capable of maintaining 50°C or greater.
  - Set water bath to 50°C
- Vortex Mixer
5.0 Reagents, Supplies, Media

- Sabouraud Dextrose agar (Emmons): example: Fisher Scientific (Product# L21827) or equivalent
- Molecular grade sterile water
- Tween-20: example: Fisher Scientific (Product# BP337-100) or equivalent
- Voriconazole example Sigma (catalog #PZ0005)
- Itraconazole example Sigma (catalog #I6675)
- Posaconazole example Sigma (catalog #SML2287)
- sterile capped glass tubes that fit
- Lysol Disinfectant concentrate (Fisher Scientific Cat # NC974686) or equivalent

5.1 RPMI media:

The Aspergillus screening plates contains four quadrants with RPMI 1640 2% glucose agar: one growth control well with no antifungal powder, one voriconazole well, one itraconazole well, and one posaconazole well.

- RPMI 1640 powder 10.4g/L (Sigma Aldrich #R1383) or equivalent
- MOPS buffer powder (Sigma Aldrich #M1254 or equivalent) 34.5 g/L
- NaOH 1mol/L
- Bacto agar 15g/L (for solid media)
- D-Glucose 20g/L

- a. Dissolve RPMI, MOPS, and glucose into 450 mL distilled H₂O, adjust to pH 7.0 with NaOH.
- b. Filter sterilize with a 0.2 micron filter (Never autoclave MOPS) and gently warm to 50°C in a hot water bath.
- c. Add 15g agar to 400mL molecular grade H₂O and autoclave for 20 minutes. **A stir bar should be added prior to autoclaving.**
- d. Put the autoclaved agar solution in the 50°C hot water bath and let cool down to 50°C.
- e. Add autoclaved agar solution to sterilized RPMI solution, adjust final volume to 1L with sterile distilled H₂O on stir plate.
- f. If using only a single batch of media, the media can be divided into 250 mL aliquots and the drug powder that will be used for screening the isolates can be added. The aliquots should be made into sterile flasks **with sterile stir bars** so that they can be stirred when the drug powders are added.

  - Voriconazole: **2mg/L** final concentration
  - Itraconazole: **4mg/L** final concentration
  - Posaconazole **0.5mg/L** final concentration
• Add powdered drug while media is at 50°C.

• Dissolve powder into media using a stir plate and sterile stir bar. If the agar starts to cool, place back in the 50°C water bath.

• Each plate will have a control well, a voriconazole well, an itraconazole well and a posaconazole well. If the quadrants/wells are not labelled, label them for orientation purposes. Use the same pattern and order for all plates to make interpretation easier.

g. The amount of media aliquoted in each well will depend on the plate that is used. Follow manufacturer’s instructions for the amount of media to be added to each well.

h. Store quadrant plates with antifungal containing medium at 4°C. Plates should be used within 12 weeks (or until the QC fails).

6.0 Supplies, Other Materials

SWUBE Applicator or cotton swab: example VWR (Catalog# 90001-126) or equivalent

4-well plate or petri dish – some examples are below

0.5 McFarland Standard

7.0 Safety Precautions

Note: All institutional safety procedures must be followed when performing this standard operating procedure.

7.1 Standard personal protective equipment should follow institutional guidelines but should consist of at least gowns, gloves, and safety glasses which should be worn at all times.

7.2 Aspergillus isolates should be handled in a certified biological safety cabinet under BSL-2 conditions.

7.3 Surfaces and supplies should be decontaminated using 1:128 Lysol solution or other decontaminant for molds approved by your institution.
8.0 Quality Control Isolates

The QC isolates should be grown on Sabouraud Dextrose agar (Emmons) slants and should be passaged fresh every time the test is run. Water cultures can be used for long term storage as described below. Prepare a number of stock solutions for each control to avoid going into the same tube over and over and risking stock contamination.

8.1 Control Strains (can be order from CDC/FDA AR Bank; https://wwwn.cdc.gov/arisolatebank/):

- *Aspergillus fumigatus* azole resistant isolate
- *Aspergillus fumigatus* azole susceptible isolate

9.0 Sample Processing

This protocol assumes that isolates to be screened have already been identified as *A. fumigatus*. This can be accomplished visually (although that will only identify down to *A. fumigatus* species complex), by DNA sequencing of the beta tubulin gene, or by MALDI-TOF with *A. fumigatus* in the database.

9.1 Assign an identification number, consistent with your laboratory numbering system, to each isolate.

9.2 Subculture isolates by transferring onto a Sabouraud dextrose agar slant using a sterile loop and incubated at 35°C. The cap for the slant should be screwed on enough to contain spores but not so much that air is unable to enter the slant.

9.3 Quality control isolates (both azole resistant and azole susceptible) should be subcultured alongside each group of tested isolates.

9.4 After 3-7 days of growth, the isolates that are producing conidia will be ready for the next steps; the slant will be used for both setting up a water stock and for susceptibility testing.

9.4.1 A mold which displays visible dark green/blue spores is ready for use.

9.4.2 A mold that remains white and has not turned green, may not be producing conidia. Make a tease prep to see if conidia are present.

9.4.3 If the mold is any other color but green, it may not be *A. fumigatus* and will not be included in the study.

9.4.4 If no conidia are present, re-inoculate the culture on a fresh slant. If it still does not turn green either process with the few conidia that are present or send to a reference laboratory for further workup. Often, patient isolates of *Aspergillus* that do not sporulate have been subjected to long term antifungal treatment and are azole resistant.
10 Preparing Isolate for Testing and Storage

The steps outlined below will be used for both creating the water stock and creating the inoculum. The same slant can be used for both steps.

10.1 Make a stock solution of diluent by adding 1ml of Tween 20 to 50 ml of molecular grade water.

10.2 Working in the BSC, add 2 ml of the water/Tween 20 solution to a 3-7 day old slant. The Tween 20 will help to get the *Aspergillus* conidia into suspension, otherwise they may just float on the surface.

10.3 Add the liquid slowly and gently, taking care not to disrupt the spores and allow them to disperse into the air.

10.4 Replace the cap, screw tightly, and gently shake the tube, allowing the water and Tween solution to dislodge the spores from the slant. The resulting liquid in the tube should become cloudy and dark with spores.

10.5 If the liquid in the tube does not become cloudy, using a sterile plastic inoculating loop, gently rub the surface of the hyphal mat to dislodge the conidia into the water. Be careful that the hyphae are not torn off of the mat. Only gentle pressure should be applied.

10.6 Using a transfer pipette, transfer 1 ml of the conidial suspension into a screwcap Cryovial tube. Label the tube and store the tube at room temperature. The conidia in this tube (water stock) will remain viable for at least 5 years. Some have been recovered 10 years later.

11 Preparing and performing susceptibility testing using *Aspergillus* screening plates

11.1 Remove the *Aspergillus* screening plates from refrigerator and allow them to reach room temperature.

11.2 Aliquot 2 ml of sterile molecular grade water into a 13 x 100 mm sterile capped Pyrex test tube.

11.3 Use the residual water in the slant from steps 10.1-10.4 to perform the next step.

11.4 Using a transfer pipet, drop 1-2 drops of the conidia suspension into the 2mL water and vortex.

11.5 Visually compare the suspension to the 0.5 McFarland Standard and make adjustments as described in 11.6 until the suspension visually matches the standard.

11.6 Adjustment is accomplished by adding more water if the suspension is too turbid and more conidial suspension if the turbidity is too low. This will yield a stock suspension of approximately 1-5 x 10^6 cells per ml.

11.7 The suspension is now ready for inoculation of an *Aspergillus* screening plate. (See figure below).
11.8 Dip a sterile cotton swab in the dilute conidia suspension and streak the entire surface of a quadrant using a back and forth motion. Re-dip the swab and streak each of the remaining three quadrants. The drug-free quadrant should be streaked first but after that the order does not matter.

11.9 Incubate the plate at 35-37°C for 48 hours.

12 Interpretation of Results

12.1 The growth control well must produce growth (see example below) in order to validate the rest of the results. Each well is marked as either growth or no growth on documentation paperwork. Any amount of growth in the drug wells or quadrants counts as growth for the purposes of this assay.

12.2 In the example above, following the picture in 11.7, the plate on the left would be marked as azole susceptible and the plate on the right would be marked as presumptive resistant to itraconazole.
13 Next steps

13.1 Isolates which are able to grow in the presence of any azole drug, must be confirmed resistant by broth microdilution, following CLSI guidelines in documents M38 and M61.


The Centers for Disease Control and Prevention is interested in receiving US azole-resistant \textit{A. fumigatus} isolates for surveillance. You can contact the Mycotic Diseases Branch about resistant isolates by emailing \texttt{aspergillus@cdc.gov}.

Information for submission of isolate to CDC can be found here:

https://www.cdc.gov/fungal/diseases/aspergillosis/antifungal-resistant.html

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) also has a published standard for performing azole resistance screening. The standard is published in this document:


\textbf{Disclaimer:} The Mycotic Diseases Branch laboratory developed this document as an example test procedure for screening to identify triazole-resistant Aspergillus fumigatus using agar plates. It is the responsibility of the testing laboratory to ensure content and format are modified as necessary to meet applicable regulatory requirements, quality management system standards, and chemical, radiological and biological safety requirements. This is not a controlled document and the described test methods are subject to change without notice. It is the responsibility of the testing laboratory to ensure the information within this document remains applicable. Contact the test developer at \texttt{gyi2@cdc.gov} to find out whether any changes have been made.

Use of trade names and commercial sources are for identification only and do not constitute endorsement by the Public Health Service, the United States Department of Health and Human Services, or the Centers for Disease Control and Prevention.